Eli Lilly & Co. (LLY.US) announced that its weight-loss drug called Zepbound outperformed competitor Novo Nordisk A/S' Wegovy (NOVOB.DK) in the first head-to-head study of the two drugs.
In the Lilly-sponsored study, people treated with Zepbound lost an average of 20% of their body weight in 72 weeks, while those receiving Wegovy lost 14%. The results confirm earlier studies of both drugs, which indicated a stronger effect of Zepbound. Full results will be published next year, Eli Lilly said. The official study document can be found here.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appImmediately following the announcement, Novo Nordisk shares lost 0.7% in value, while Eli Lily shares gained nearly 2% before the session began.
LLY shares gain before the opening of the session on Wall Street. Source: Yahoo Finance
Meanwhile, Novo Nordisk shares are bouncing off the resistance zone set by the 50-day EMA (blue curve) and losing nearly 1.2% today. Source: xStation
